Oruka Therapeutics, Inc. ORKA R&D credit carryforward
R&D credit carryforward at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.
The official record: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s r&d credit carryforward.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s r&d credit carryforward?
- Oruka Therapeutics, Inc. (ORKA) reported r&d credit carryforward of $5.37M in Q4 2025.
- What does r&d credit carryforward mean?
- This represents the accumulated value of research and development tax credits that have not yet been utilized to offset tax liabilities. For a clinical-stage biotechnology company, these carryforwards represent a significant future tax benefit that can be applied against future taxable income. It reflects the company's historical investment in innovation and provides insight into potential future cash flow preservation.